Squarepoint’s KalVista Pharmaceuticals KALV Stock Holding History

Squarepoint’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.9M	Buy	+143,966	New	+$2.32M	﹤0.01%	1914
2025 Q3	–	Sell	-26,386	Closed	-$298K	–	4675
2025 Q2	$298K	Buy	+26,386	New	+$323K	﹤0.01%	3689
2024 Q4	–	Sell	-25,749	Closed	-$298K	–	5275
2024 Q3	$298K	Buy	+25,749	New	+$324K	﹤0.01%	3449
2023 Q2	–	Sell	-14,432	Closed	-$113K	–	3793
2023 Q1	$113K	Buy	+14,432	New	+$108K	﹤0.01%	2945
2021 Q3	–	Sell	-8,919	Closed	-$214K	–	3174
2021 Q2	$214K	Sell	8,919 -14,822	-62%	-$388K	﹤0.01%	2778
2021 Q1	$610K	Buy	+23,741	New	+$624K	﹤0.01%	1869
2020 Q3	–	Sell	-14,853	Closed	-$180K	–	2664
2020 Q2	$180K	Sell	14,853 -61,057	-80%	-$649K	﹤0.01%	1852
2020 Q1	$581K	Sell	75,910 -47,133	-38%	-$636K	0.01%	962
2019 Q4	$2.19M	Sell	123,043 -844	-0.7%	-$11K	0.01%	854
2019 Q3	$1.44M	Buy	123,887 +52,643	+74%	+$851K	0.01%	997
2019 Q2	$1.58M	Buy	+71,244	New	+$1.67M	0.02%	984

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Squarepoint's KALV Position: Q1 2026 in Review

Squarepoint opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 143,966 shares worth $2.9M. The stake represents ﹤0.01% of the portfolio and ranks #1914 among its holdings. This is a return to the name: Squarepoint previously reported a position in KALV as recently as Q2 2025.

Squarepoint first reported a position in KALV in Q2 2019 and has held it in 11 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Squarepoint held 143,966 shares of KalVista Pharmaceuticals worth $2.9M as of Q1 2026.
KalVista Pharmaceuticals was a new Squarepoint position in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1914 holding.
Squarepoint first reported a position in KalVista Pharmaceuticals in Q2 2019 and has held it in 11 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.